![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, January 16, 2009 2:57:42 PM
DNAPrint Genomics is no "sham company." It is, as we very well know, a company that is struggling with financing issues. That does not, in any way, shape, or form, make it a "sham company."
As for the lab instrument that Sarah told me was currently down, she said it should be back up and running within "a few weeks."
What do you expect from microcap research and development stocks, struggling with financing issues? I think DNAG has been extremely reserved in the issuance of new shares, relative to other companies in similar situations. People who buy such stocks only have themselves to blame, if they don't understand the realities surrounding such stocks. Get-rich-quick-with-no-risk dreams are delusional.
In my opinion, DNAPrint Genomics well deserves to succeed. It is gratifying to see that the constant reports of its demise, have been greatly exaggerated. (For some reason, I never see any retractions from the "detractor" aliases, no matter how often they are proven wrong.)
Daniel
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM